SOBI:OMXSTOSwedish Orphan Biovitrum AB Analysis

Swedish Orphan Biovitrum (SOBI) is trading around SEK 385, comfortably above its 20‑day (≈SEK 397), 50‑day (≈SEK 368) and 200‑day (≈SEK 317) moving averages, indicating a short‑term bullish bias despite a bearish MACD histogram. The stock sits near a technical support zone at SEK 364 and faces resistance around SEK 433, while the RSI hovers at 50, suggesting neither over‑bought nor over‑sold conditions. Fundamentally, the company posted 5.2% revenue growth, a robust 41% adjusted EBITDA margin in Q4, and a forward PE of ~25x versus an industry average of ~25x, yet its trailing PE of 283x signals severe overvaluation relative to peers and a DCF‑derived fair value of roughly SEK 211.
Recent material news includes the completion of the Arthrosi Therapeutics acquisition, expanding the pipeline into gout treatment, and a Capital Markets Day that outlined a mid‑term growth strategy, both of which could underpin future earnings upside. However, high debt levels (≈SEK 11.5 bn) and a 35% 30‑day volatility, coupled with a declining trading volume, raise liquidity and risk concerns that temper short‑term enthusiasm.